Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

11.25USD
19 Sep 2017
Change (% chg)

$0.50 (+4.65%)
Prev Close
$10.75
Open
$10.90
Day's High
$11.25
Day's Low
$10.75
Volume
80,109
Avg. Vol
51,404
52-wk High
$14.60
52-wk Low
$5.50

Select another date:

Tue, Aug 8 2017

BRIEF-Stemline Therapeutics files for mixed shelf offering of up to $175 mln

* Stemline Therapeutics Inc files for mixed shelf offering of up to $175 million - SEC filing‍​ Source text: (http://bit.ly/2wFKm1k) Further company coverage:

BRIEF-Stemline Therapeutics Q2 loss per share $0.66

* Stemline Therapeutics reports second quarter 2017 financial results

BRIEF-Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN

* Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN and safety experience across multiple indications, today at EHA

BRIEF-Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 BPDCN trial

* Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 bpdcn trial at upcoming European Hematology Association (EHA) meeting Source text for Eikon: Further company coverage:

BRIEF-Stemline Therapeutics Q1 loss per share $0.67

* Stemline therapeutics reports first quarter 2017 financial results

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn

Select another date: